

29 April 2026

Australian Securities Exchange
20 Bridge Street
Sydney NSW 2000

Q3 FY26 Quarterly Activities Report

Melbourne, Victoria | Alcidion Group Limited (ASX:ALC) ('Alcidion' or the 'Company') has today released its Appendix 4C and Quarterly Activities Report for the quarter ended 31 March 2026 (Q3 FY26).

Highlights:

- Q3 FY26 positive operating cashflow of \$1.7M driven by cash receipts of \$14.5M
- Q3 new TCV sales of \$11.7M
 - Hywel Dda and South Tees - contract expansions for Miya Emergency (Miya ED)
 - Gold Coast Health – new contract for Remote Patient Monitoring (Virtual Care)
 - Several existing contract renewals for Patienttrack and PCS
- Selected as preferred provider for University Hospital Sussex NHS Foundation Trust's (UHSussex) new EPR solution – the contract remains on track for signing in May 2026
- As of 31 March 2026, FY26 contracted (sold & renewal) revenue of \$43.8M (excluding UHSussex)
- Reconfirming FY26 financial guidance of:
 - Revenue expected to exceed \$50.0M with EBITDA in excess of \$5.0M; and
 - Operating cashflow to remain positive in-line with FY25 operating cashflow of \$5.8M
- Cash balance of \$15.1M and no debt as of 31 March 2026

Alcidion CEO and Managing Director, Kate Quirke said: "Q3 maintained the positive and sustained momentum for Alcidion, with contract expansions for our emergency department module, significant renewal contracts signed and importantly our first site in QLD for Miya Precision."

"During the period, we continued to build on our existing relationships in the UK market, with Hywel Dda and South Tees both expanding their contracts to include use of our Miya ED module, further validating the land and expand growth strategy. Miya ED, specifically tailored for the unique challenges of an emergency department, digitises emergency department processes and integrates disparate patient data to provide crucial visibility of patient status and clinical documentation."

"We are particularly proud of the growing market demand for Miya ED, a recently developed module of Miya Precision that continues to demonstrate our ability to not only innovate but rapidly commercialise new functionality that adds value to our customers."

"In March, we signed a 5-year contract with Gold Coast Health to deliver an end-to-end remote patient monitoring solution, enabling the health service to extend virtual care into patients' homes. This is an important new customer for Alcidion, providing an initial entry into a digitally progressive health care organisation, whilst also expanding our market presence in Australia with the first deployment of Miya Precision in Queensland. Remote patient monitoring is transforming the way health services think about capacity. It is no longer just about hospital beds, but about meeting patients where they are. We are proud to partner with Gold Coast Health on this initiative, which reflects a growing momentum across the sector toward virtual care models that are better for patients and more sustainable for health systems."

“Contract negotiations continue to progress with UHSussex in relation to Alcidion supplying their new EPR solution. We remain on track to finalise the agreement in May 2026, with an upfront license expected to contribute materially to revenue in FY26 and underpinning our current financial guidance.”

“We further extended our relationship with North Cumbria Integrated Care (NCIC) who expanded their contract with us to include Smartpage non-clinical, adding to the introduction of Smartpage clinical last quarter.”

“During the quarter we signed several renewal contracts for PCS and Patientrack in the UK, including PCS extensions at Harrogate, Dorset and Liverpool Heart and Chest Trusts.”


“It has been a very busy quarter for Alcidion reflecting the increasing market presence Alcidion has established across ANZ and UK, further cementing our position as a provider of choice for healthcare technology that delivers sustainable efficiencies and supports patient care.”

Financial Update

Alcidion generated Q3 new sales of \$11.7M of which approximately 90% is recurring product revenue and 10% is non-recurring services (product implementation) revenue.

Cash receipts from customers in Q3 were \$14.5M, leading to positive operating cashflow of \$1.7M.

Product development and operating costs were \$3.4M. As expected, this was higher than the prior two quarters reflecting payments for third-party partner products associated with Alcidion’s recently expanded Leidos contract and the provision of Mizaic to NCIC.



Payments made to related parties and their associates totalled \$0.26M for the quarter, as noted in item 6 of the Company’s Appendix 4C. These payments relate solely to Directors’ remuneration.

Outlook

As of 31 March 2026, Alcidion has FY26 contracted (sold and renewal) revenue of \$43.8M, up 9% on the prior corresponding period (pcp). This does not include any revenue contribution from the University Hospitals Sussex EPR contract (expected to be finalised in May 2026) or other potential new contract wins which may occur over the final quarter of the financial year.

For personal use only

As illustrated by the graph of cash receipts (refer above), Q4 is historically Alcidion's largest period for customer receipts and as a result the Company would expect Q4 FY26 customer receipts to be the highest for the year.

Alcidion reconfirms its FY26 financial guidance of:

- Revenue expected to exceed \$50.0M with EBITDA in excess of \$5.0M; and
- Operating cashflow to remain positive and in-line with FY25 operating cashflow of \$5.8M

Investor Webcast

Alcidion Group Managing Director Kate Quirke will host a webcast with investors via Zoom on Wednesday, 29 April 2026 at 11:00am Australian Eastern Standard Time (AEST).

To register for the webcast, please follow this link:

https://us02web.zoom.us/webinar/register/WN_H1xmy-jASKanWXFwRLvdg

Registered participants will receive an email containing the Zoom access link and phone dial-in details.

ENDS

Authorised for ASX release by the Board of Directors of Alcidion Group Limited

For further information, please contact:

Investor Relations

investor@alcidion.com

About Alcidion

Alcidion Group Limited (Alcidion) has a simple purpose, that is, to transform healthcare with proactive, smart, intuitive technology solutions that improve the efficiency and quality of patient care in healthcare organisations, worldwide.

Alcidion offers a complementary set of software products and technical services that create a unique offering in the global healthcare market. Based on the flagship product, Miya Precision, the solutions aggregate meaningful information to centralised dashboards, support interoperability, facilitate communication and task management in clinical and operational settings and deliver Clinical Decision Support at the point of care; all in support of Alcidion's mission to improve patient outcomes.

Since listing on the ASX in 2011, Alcidion has acquired multiple healthcare IT companies and expanded its foothold in the UK, Australia, and New Zealand to now service over 400 hospitals and 87 healthcare organisations, with further geographical expansion planned.

With over 20 years of healthcare experience, Alcidion brings together the very best in technology and market knowledge to deliver solutions that make healthcare better for everyone.

www.alcidion.com

© Alcidion Group Limited 2026

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

ALCIDION GROUP LIMITED

ABN

77 143 142 410

Quarter ended ("current quarter")

31 March 2026

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	14,548	31,505
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(3,405)	(5,781)
(c) advertising and marketing	(212)	(658)
(d) leased assets	-	-
(e) staff costs	(6,267)	(19,513)
(f) administration and corporate costs	(1,638)	(4,054)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	35	124
1.5 Interest and other costs of finance paid	(14)	(46)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other – GST/VAT received/(paid)	(1,373)	(2,466)
1.9 Net cash from / (used in) operating activities	1,674	(889)

2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(g) entities	-	-
(h) businesses	-	-
(i) property, plant and equipment	(68)	(100)
(j) investments	-	-
(k) intellectual property	-	-
(l) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(68)	(100)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (Payment for principal portion of lease liabilities)	(177)	(548)
3.10	Net cash from / (used in) financing activities	(177)	(548)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	14,195	17,697
4.2	Net cash from / (used in) operating activities (item 1.9 above)	1,674	(889)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(68)	(100)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(177)	(548)
4.5	Effect of movement in exchange rates on cash held	(519)	(1,055)
4.6	Cash and cash equivalents at end of period	15,105	15,105

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	14,658	13,744
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (TDs)	447	451
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	15,105	14,195

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	258
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	150	51
7.4	Total financing facilities	150	51
7.5	Unused financing facilities available at quarter end		99
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	WBC corporate credit card facility secured against cash deposits; interest charged at 14.25% on overdue accounts		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	1,674
8.2	Cash and cash equivalents at quarter end (item 4.6)	15,105
8.3	Unused finance facilities available at quarter end (item 7.5)	99
8.4	Total available funding (item 8.2 + item 8.3)	15,204
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 29 April 2026

Authorised by: The Board of Directors

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.